Yarrow Bioscience gets 7.2% passive Invus stake

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. (YARW) is reported to have a significant shareholder group led by Invus Public Equities, L.P. and related entities, which together with Raymond Debbane may be deemed to beneficially own 675,000 shares of common stock, representing 7.2% of the company as of mid-September 2026.

Invus Public Equities directly holds 591,472 shares, and Avicenna Life Sci Master Fund LP directly holds 83,528 shares, with various general partners and managing members, including Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master GP LLC and Ulys, L.L.C., deemed to share beneficial ownership through control relationships. The reporting group certifies that the securities were not acquired or held for the purpose of changing or influencing control of Yarrow Bioscience, other than activities solely in connection with a nomination under the specified rule.

Key Figures

Shares held by Invus Public Equities, L.P.: 591,472 shares Shares held by Avicenna Life Sci Master Fund LP: 83,528 shares Total shares beneficially owned by Reporting Persons: 675,000 shares +5 more

8 metrics

Shares held by Invus Public Equities, L.P. 591,472 shares Common stock of Yarrow Bioscience held directly as of September 11, 2026

Shares held by Avicenna Life Sci Master Fund LP 83,528 shares Common stock of Yarrow Bioscience held directly as of September 11, 2026

Total shares beneficially owned by Reporting Persons 675,000 shares Aggregate Yarrow Bioscience common shares the Reporting Persons may be deemed to beneficially own

Ownership percentage of Invus Public Equities, L.P. 6.3% Percent of Yarrow Bioscience common stock class as of September 2026

Ownership percentage of Avicenna Life Sci Master Fund LP 0.9% Percent of Yarrow Bioscience common stock class as of September 2026

Ownership percentage of full Reporting Person group 7.2% Percent of Yarrow Bioscience common stock that the Reporting Persons may be deemed to beneficially own

Shares outstanding used for ownership calculation 8,572,309 shares Shares outstanding as of September 11, 2026, based on issuer information

Additional shares from underwriters option 865,384 shares Additional Yarrow Bioscience shares from exercise of the underwriters option reported September 14, 2026

Key Terms

beneficially own, sole voting power, sole dispositive power, percent of class, +2 more

6 terms

beneficially own financial

"may be deemed to beneficially own the Shares directly held"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole voting power financial

"5 | Sole Voting Power 591,472.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"7 | Sole Dispositive Power 591,472.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

percent of class financial

"Percent of class: As of September 14, 2026, each of the Reporting Persons"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

underwriters option financial

"an additional 865,384 Shares resulting from the exercise of the underwriters option"

Schedule 13G regulatory

"were not acquired and are not held for the purpose of or with the effect"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many YARW shares does Invus Public Equities directly hold?

Invus Public Equities, L.P. directly holds 591,472 shares of Yarrow Bioscience common stock as of September 11, 2026, described as the “Shares” of the issuer in the ownership section.

What is the total YARW stake reported by the Invus-related group?

The Reporting Persons, including Invus entities and Raymond Debbane, may be deemed to beneficially own 675,000 shares of Yarrow Bioscience common stock, representing 7.2% of the class as of mid-September 2026.

What percentage of YARW does Invus Public Equities report owning?

Invus Public Equities, L.P. reports beneficial ownership of 6.3% of Yarrow Bioscience’s common stock, based on its 591,472 shares and the issuer’s outstanding share count and additional shares from an underwriters option.

How many YARW shares does Avicenna Life Sci Master Fund LP own?

Avicenna Life Sci Master Fund LP directly holds 83,528 shares of Yarrow Bioscience common stock, corresponding to 0.9% of the class, with related entities Avicenna GP and Ulys deemed to beneficially own those shares through control relationships.

Is the Invus group seeking control of Yarrow Bioscience (YARW)?

The Reporting Persons certify that the securities “were not acquired and are not held for the purpose of or with the effect of changing or influencing the control” of Yarrow Bioscience, other than activities solely in connection with a nomination under the referenced rule.

What YARW share count was used to calculate the ownership percentages?

Ownership percentages are based on 8,572,309 shares outstanding as of September 11, 2026, plus an additional 865,384 shares from the exercise of the underwriters option to purchase additional shares, as reported by Yarrow Bioscience.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:57 PM Accepted by SEC EDGAR 09/17/2026 - 04:57 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Yarrow Bioscience, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

92941V407

(CUSIP Number)

09/11/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Invus Public Equities, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

BERMUDA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 591,472.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 591,472.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

591,472.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Invus Public Equities Advisors, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 591,472.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 591,472.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

591,472.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Invus Global Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 591,472.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 591,472.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

591,472.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Siren, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 591,472.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 591,472.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

591,472.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.3 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Avicenna Life Sci Master Fund LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 83,528.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 83,528.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

83,528.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Avicenna Life Sci Master GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 83,528.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 83,528.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

83,528.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Ulys, L.L.C.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 83,528.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 83,528.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

83,528.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.9 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92941V407

1

Names of Reporting Persons

Raymond Debbane

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PANAMA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 675,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 675,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

675,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Yarrow Bioscience, Inc.
(b)	Address of issuer's principal executive offices: 470 James Street, Suite 007, New Haven, CT 06513
Item 2.
(a)	Name of person filing: See Item 2(c) below.
(b)	Address or principal business office or, if none, residence: See Item 2(c) below.
(c)	Citizenship: (i) Invus Public Equities, L.P. ("Invus Public Equities") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Bermuda limited partnership (ii) Invus Public Equities Advisors, LLC ("Invus PE Advisors") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iii) Invus Global Management, LLC ("Global Management") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (iv) Siren, L.L.C. ("Siren") c/o The Invus Group, LLC, 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (v) Avicenna Life Sci Master Fund LP ("Avicenna Fund") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Cayman Islands limited partnership (vi) Avicenna Life Sci Master GP LLC ("Avicenna GP") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (vii) Ulys, L.L.C. ("Ulys") 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Delaware limited liability company (viii) Mr. Raymond Debbane 750 Lexington Avenue, 30th Floor, New York, NY 10022 Citizenship: Panama The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP Number(s): 92941V407
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of September 11, 2026, Invus Public Equities directly held 591,472 shares of common stock (the "Shares") of Yarrow Bioscience, Inc. (the "Issuer"), and Avicenna Fund directly held 83,528 Shares. Invus PE Advisors, as the general partner of Invus Public Equities, controls Invus Public Equities and, accordingly, may be deemed to beneficially own the Shares directly held by Invus Public Equities. Global Management, as the managing member of Invus PE Advisors, controls Invus PE Advisors and, accordingly, may be deemed to beneficially own the Shares that Invus PE Advisors may be deemed to beneficially own. Siren, as the managing member of Global Management, controls Global Management and, accordingly, may be deemed to beneficially own the Shares that Global Management may be deemed to beneficially own. Avicenna GP, as the general partner of Avicenna Fund, controls Avicenna Fund and, accordingly, may be deemed to beneficially own the Shares directly held by Avicenna Fund. Ulys, as the managing member of Avicenna GP, controls Avicenna GP and, accordingly, may be deemed to beneficially own the Shares that Avicenna GP may be deemed to beneficially own. Mr. Raymond Debbane, as the managing member of Siren and Ulys, controls Siren and Ulys and, accordingly, may be deemed to beneficially own the Shares that Siren and Ulys may be deemed to beneficially own.
(b)	Percent of class: As of September 14, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page. Calculations of the percentage of Shares beneficially owned are based on (i) 8,572,309 Shares outstanding as of September 11, 2026, based on information provided by the Issuer on Form 424(b)(5) as filed with the Securities and Exchange Commission on September 11, 2026 and (ii) an additional 865,384 Shares resulting from the exercise of the underwriters option to purchase additional Shares as reported by the Issuer on Form 8-K as filed with the Securities and Exchange Commission on September 14, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See each cover page hereof.
	(ii) Shared power to vote or to direct the vote: See each cover page hereof.
	(iii) Sole power to dispose or to direct the disposition of: See each cover page hereof.
	(iv) Shared power to dispose or to direct the disposition of: See each cover page hereof.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

Each of the Reporting Persons hereby makes the following certification: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Invus Public Equities, L.P.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner
Date:	09/17/2026

Invus Public Equities Advisors, LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	09/17/2026

Invus Global Management, LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	09/17/2026

Siren, L.L.C.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	09/17/2026

Avicenna Life Sci Master Fund LP

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner
Date:	09/17/2026

Avicenna Life Sci Master GP LLC

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, Chief Executive Officer
Date:	09/17/2026

Ulys, L.L.C.

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane, President
Date:	09/17/2026

Raymond Debbane

Signature:	/s/ Raymond Debbane
Name/Title:	Raymond Debbane
Date:	09/17/2026